Serum copeptin as a biomarker of hypertension in children with obesity

Zeynep Gor1, Digdem Bezen2, Yelda Turkmenoglu1

  • 1Department of Pediatrics, Health Science University, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey.

Insights

Children with obesity and hypertension have higher levels of copeptin and uric acid, and lower potassium. These biomarkers may aid in diagnosing and monitoring pediatric hypertension.

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Health in Children
  • Metabolic Disorders

Background:

  • Hypertension is increasingly prevalent in obese children.
  • The specific roles of copeptin and uric acid in pediatric obesity-related hypertension are not well understood.
  • This study investigates novel biomarkers for hypertension in this population.

Purpose of the Study:

  • To examine the relationship between hypertension and serum copeptin and uric acid levels in children with obesity.
  • To identify potential diagnostic and monitoring markers for pediatric hypertension.

Main Methods:

  • Study included 80 children with obesity admitted to a hospital.
  • Patients were categorized into hypertensive and non-hypertensive groups.
  • Serum copeptin levels were quantified using enzyme-linked immunosorbent assay.

Main Results:

  • Significantly elevated copeptin levels were observed in hypertensive children compared to non-hypertensive controls (p < 0.0001).
  • Hypertensive children also showed higher serum uric acid and lower serum potassium levels (p < 0.01).
  • A positive correlation was found between blood sodium and copeptin levels (p = 0.037).

Conclusions:

  • Obese children with hypertension exhibit higher serum copeptin and uric acid, and lower blood potassium.
  • Copeptin levels demonstrated a positive correlation with blood sodium levels.
  • Serum uric acid, potassium, and sodium, alongside copeptin, may be crucial for managing pediatric hypertension.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
138
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
36
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
3.0K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
35